Actelion reports first full quarter of Opsumit sales

Actelion Ltd. (SIX:ATLN) reported CHF15 million ($16.9 million) in the first full quarter of sale of the pulmonary arterial hypertension (PAH) drug. The company launched the tissue-targeting endothelin receptor antagonist in the U.S. in November and in Canada and Europe earlier this year. In February, Actelion said it expects peak sales of Opsumit to exceed those of its PAH drug Tracleer bosentan, which had 1Q14 sales of CHF383 million ($432.1 million), up from CHF375 million ($394.7 million) in 1Q13. ...